Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
ID: 360906Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360906
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine," aimed at supporting integrative, cross-disciplinary research projects focused on understanding the genomic factors involved in Alzheimer's Disease (AD) and Alzheimer's Disease Related Dementias (ADRD). The initiative seeks to leverage innovative techniques and advanced analytical methods, including machine learning and comparative genomic analysis, to explore the genomic drivers of neurodegeneration through sophisticated disease models and interdisciplinary approaches. This cooperative agreement does not require cost sharing and is open to a wide range of eligible applicants, including non-domestic entities and tribal governments, with applications expected to be solicited starting in August 2026. For further inquiries, interested parties may contact Dr. Alison Yao at 301-827-7264 or via email at yaoal@nia.nih.gov.

    Point(s) of Contact
    Alison Yao, Ph.D.
    (301) 827-7264
    yaoal@nia.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease Risk
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's and Related Dementias Disease Risk." This initiative aims to foster research that integrates epidemiologic, genomic, and mechanistic studies to uncover the molecular and cellular determinants of resilience against Alzheimer's disease (AD) and related dementias (ADRD) through data-driven, systems-based approaches, including artificial intelligence and machine learning. The program is particularly significant as it seeks to generate high-dimensional molecular data from brain and peripheral tissues, facilitating the discovery of molecular predictors of resilience across diverse populations. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the opportunity, which is expected to utilize the U01 activity code. For further inquiries, potential applicants can contact Dr. Suzana Petanceska at petanceskas@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is February 26, 2026, with a projected award date of April 5, 2027.
    Translational Center for Accelerating the Use of Digital Health Technologies Data in AD/ADRD Research
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Translational Center for Accelerating the Use of Digital Health Technologies Data in AD/ADRD Research." This initiative aims to establish a comprehensive center focused on developing infrastructure and best practices for the effective use of digital health technology data in Alzheimer's Disease (AD) and related dementias research. The center will create a cloud-based, federated data repository that adheres to the FAIR principles, facilitating the secure storage, processing, and integration of diverse data types generated from AD/ADRD studies. While applications are not currently being solicited, interested parties are encouraged to prepare collaborative proposals in anticipation of the official announcement, with an estimated synopsis posting date of February 27, 2026, and a projected award date of April 25, 2027. For further inquiries, potential applicants can contact Dr. Nadezda Radoja at nadezda.radoja@nih.gov or by phone at 240-447-1938.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD)" (PAR-23-258), aimed at supporting the validation of biomarkers to enhance therapy development and clinical practices. This initiative seeks applications that focus on achieving rigorous analytical and clinical validation of biomarkers, aligning with the standards set by the FDA’s Biomarker Qualification Program. The program is crucial for advancing research strategies that validate candidate biomarkers across diverse populations, thereby facilitating their use in clinical trials and medical product development. Interested applicants, including various educational and community organizations, must submit their proposals by March 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Understanding Cerebellar Contributions to Cognitive and Affective Functions in Aging and Alzheimer's Disease/Alzheimer's Disease-Related Dementias
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming Notice of Funding Opportunity (NOFO) aimed at advancing research on the cerebellum's role in cognitive and affective functions related to aging and Alzheimer's disease (AD) as well as Alzheimer's disease-related dementias (ADRD). This initiative seeks to enhance understanding of the cerebellum's physiology and neuroanatomy, encouraging a variety of research approaches, including basic studies, secondary data analyses, and intervention-focused research. The NOFO is particularly significant as it aims to identify potential targets for interventions that could promote cognitive reserve and delay the onset of AD/ADRD. Interested researchers are encouraged to prepare collaborative proposals, with applications expected to be solicited in the future; for inquiries, contact Matt Sutterer, Ph.D., at matt.sutterer@nih.gov. The estimated synopsis post date is August 6, 2026, with a projected award date of July 6, 2027.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.